Antivirals/Anti-Infectives

Tap into PPD’s wealth of experience in infectious disease studies. Antiviral/anti-infective (AVAI) is one of our leading therapeutic areas (ranked by revenue), where we have more than 10 years’ experience successfully conducting multinational studies covering a broad range of agents.

Global Investigator Network

PPD helps you obtain comprehensive demographics and performance metrics by utilizing our:

• Database of more than 670 investigators working in 34 countries
• Experience in a broad range of infectious disease indications
• Access to specialized clinical sites with proven trial experience

A Team of Experts

Led by senior managers with extensive drug development experience in infectious disease indications, PPD assists you in the early planning stages to develop the best possible operational scenario to conduct an individual study or a full development program successfully.

Experience

PPD’s in-depth experience in antiviral and anti-infective development spans multiple indications including:

• Aspergillosis
• Bacteremia
• Bronchitis
• Candidemia
• Chlamydiae
• Cholera
• Cytomegalovirus infection
• Dermatophytosis
• Endocarditis
• Hepatitis A, B and C
• HIV
• Human papillomavirus (HPV) associated diseases
• Influenza
• Neutropenia
• Osteomyelitis
• Otitis externa
• Otitis media
• Pelvic infection
• Periostitis
• Pneumonia
• Uti prophylaxis
• Meninge diptheria vaccine
• Meningitis
• Respiratory syncytial virus
• Sepsis
• Sinusitis
• Tetanus diphtheria vaccine
• Tinea
• Tuberculosis

HIV

PPD leads the industry in global HIV therapeutic development:

• More than 20 years experience with HIV trials in a broad range of indications and patient populations
• Offices around the world for access to target patient populations
• 500 HIV experts in our global investigator database
• International regulatory expertise

Our core regions for HIV development include Europe, Latin America, Australia, North America, South Africa and Southeast Asia. In addition, our government contract HIV experience includes various therapeutic programs in AIDS/HIV vaccine and prevention research.

Hepatitis

Over the past six years, PPD has conducted more than 56 hepatitis trials across six continents involving more than 16,000 patients and 1,100 sites. Our core regions for hepatitis development include Europe, Latin America, North America, Australia, South Africa and Southeast Asia.

Antibiotics

PPD has managed 68 recent clinical trials enrolling more than 28,000 patients in 3,700 sites across Europe, Latin America, the Middle East, North America and Southeast Asia. Key indications include influenza, pneumonia, sinusitis and otitis media.

Antifungals

Since 2000, PPD has managed 37 Phase I-IV studies involving antifungal drug classes, including invasive fungal infections, aspergillosis, candidiasis, cryptococcosis and neutropenia. These studies included 6,800 patients and more than 630 sites in Europe, Latin America, North America and Southeast Asia.